Inflammation and cancer
Open accessThe DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index; 8 of the 94 sources its claims cite were checked for support.
Abstract
Recent data have expanded the concept that inflammation is a critical component of tumour progression. Many cancers arise from sites of infection, chronic irritation and inflammation. It is now becoming clear that the tumour microenvironment, which is largely orchestrated by inflammatory cells, is an indispensable participant in the neoplastic process, fostering proliferation, survival and migration. In addition, tumour cells have co-opted some of the signalling molecules of the innate immune system, such as selectins, chemokines and their receptors for invasion, migration and metastasis. These insights are fostering new anti-inflammatory therapeutic approaches to cancer development.
Overview
CoChat Summary
TL;DR
This review argues that inflammation is a critical component of tumour progression, with inflammatory cells and their mediators fostering proliferation, survival, angiogenesis, invasion and metastasis. It synthesizes evidence linking chronic infection/inflammation to cancer and discusses anti-inflammatory therapeutic opportunities.
Key findings
- Many cancers arise from sites of infection, chronic irritation and inflammation; the tumour microenvironment, largely orchestrated by inflammatory cells, is an indispensable participant in neoplasia, fostering proliferation, survival and migration.
- Upwards of 15% of malignancies worldwide are attributable to infections, a global total of 1.2 million cases per year; chronic inflammatory conditions are associated with neoplasms including colorectal carcinoma in inflammatory bowel disease and gastric cancer with chronic *Helicobacter pylori* infection, the second most common cancer globally.
- In MMTV-PyMT mammary cancer mice crossed with CSF-1-null (*Csf1op*) mice, absence of CSF-1 had no apparent early consequence, but late-stage invasive carcinoma and pulmonary metastases were significantly attenuated; targeting CSF-1 to mammary epithelium restored macrophage recruitment, primary tumour development and metastatic potential.
- Long-term aspirin/NSAID use reduces colon cancer risk by 40–50% and may be preventative for lung, oesophagus and stomach cancer; tumour cells also co-opt innate immune signalling molecules such as selectins, chemokines and their receptors for invasion, migration and metastasis.
Methods
- Narrative review; no primary experiments or new patient/animal data are reported.
- Synthesizes published literature on inflammation, innate immunity, wound healing, inflammatory cell types, chemokines, chronic inflammation-associated cancers, selectin/MMP biology and anti-inflammatory therapy.
- Main analysis is conceptual synthesis and interpretation of cited studies; no systematic search strategy, inclusion criteria or quantitative meta-analysis is described.
Limitations
- The paper states that the acquired immune response to cancer is intimately related to the inflammatory response but is beyond the scope of the article.
- Evident from the text: as a narrative review, it lacks a systematic search or formal evidence appraisal, and conclusions depend on the cited studies.
- Evident from the text: many molecular and cellular mechanisms mediating the inflammation–cancer relationship remain unresolved, and therapeutic implications are largely based on observational, animal or preclinical evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 1 Not valid · 66 Not checked · 35 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition to altering the local balance of pro-angiogenic factors during melanoma development, during human cervical carcinogenesis, TAMs express VEGF-C and VEGF-D as well as the VEGF receptor-3 (VEGFR-3), all of which are implicated in formation of lymphatic vessels and lymphatic metastases17.”
What the sources say
- Supportedcites [17] Schoppmann S, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol. 2002;161:947–956. doi: 10.1016/S0002-9440(10)64255-1. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Abstract (p.1) states that in human cervical cancers the VEGF-C- and VEGF-D-producing stromal cells were identified in situ as a subset of activated TAMs (CD68, CD23, CD14) that 'also expressed the VEGF-C-and VEGF-D-specific tyrosine kinase receptor VEGFR-3'. The Discussion reinforces this: 'All VEGF-C-and VEGF-D-producing TAMs co-expressed also the corresponding tyrosine kinase receptor VEGFR-3', and links their density to peritumoral lymphatic microvessel density, lymphangiosis carcinomatosa and lymph-node metastasis, i.e. lymphatic vessel formation and lymphatic spread. The melanoma clause of the citing sentence belongs to a different citation and was not judged here. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Tumour cells produce various cytokines and chemokines that attract leukocytes.”
What the sources say
- Could not verifycites [11] Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med. 2000;248:171–183. doi: 10.1046/j.1365-2796.2000.00742.x. [DOI] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Helicobacter pylori section (p. 9) describes white blood cells being attracted during inflammation, followed by increased cytokine production. The Mechanisms section (p. 2) discusses inflammation caused by infection. Neither passage says that tumour cells produce cytokines or chemokines to attract leukocytes; searches for those terms found no supporting passage. (LLM, conf=0.76)
- Partly supportedcites [12] Wahl LM, Kleinman HK. Tumor-associated macrophages as targets for cancer therapy. J Natl Cancer Inst. 1998;90:1583–1584. doi: 10.1093/jnci/90.21.1583. [DOI] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
On p. 1, the paper says tumor-derived attractants, including monocyte chemotactic protein-1, recruit tumor-associated macrophages to tumors. It also lists several tumor-derived cytokines, but describes them as reducing macrophage cytotoxicity, not attracting leukocytes. The claim extends the recruitment point beyond the macrophages and attractant discussed in the paper. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The key difference between PyMT mice and PyMT/Csf1op/Csf1op mice is not in the apparent proliferative capacity of neoplastic epithelial cells, but in the failure to recruit mature macrophages into neoplastic tissue in the absence of CSF-1.”
What the sources say
- Supportedcites [21] Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001;193:727–740. doi: 10.1084/jem.193.6.727. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Introduction reports that CSF-1 deficiency did not affect primary mammary tumor growth but delayed macrophage recruitment. The Results section (“Absence of CSF-1 Does Not Effect Growth of the Primary Mammary Tumor”) found no significant difference in tumor-cell proliferation, and the Discussion reports no macrophage infiltration at the tumor site in CSF-1-null PyMT mice. Page numbers are not provided in our copy. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Genetic and functional experiments indicate that neutrophils, mast cells, eosinophils and activated T lymphocytes also contribute to malignancies by releasing extracellular proteases, pro-angiogenic factors and chemokines11,23–26.”
What the sources say
- Partly supportedcites [11] Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med. 2000;248:171–183. doi: 10.1046/j.1365-2796.2000.00742.x. [DOI] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Mechanisms section (p. 2) says inflammatory phagocytes produce reactive oxygen and nitrogen species that can favor carcinogenesis. The H. pylori section (p. 9) links recruited white blood cells and cytokines to oxidative DNA damage. Neither passage establishes the claimed contribution of all four named cell types through extracellular proteases, pro-angiogenic factors, and chemokines, or cites genetic and functional experiments for it. (LLM, conf=0.78)
- Not checked yetcites [23] DiCarlo E, et al. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood. 2001;97:339–345. doi: 10.1182/blood.v97.2.339. [DOI] [PubMed] [Google Scholar] source
- Partly supportedcites [24] Coussens LM, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 1999;13:1382–1397. doi: 10.1101/gad.13.11.1382. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Conclusion (page unavailable) links mast cells to angiogenesis during premalignant squamous carcinogenesis through the release of pro-angiogenic proteases. The paper does not establish the claimed roles of neutrophils, eosinophils or activated T lymphocytes, or their release of chemokines. (LLM, conf=0.86)
- Not checked yetcites [25] Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000;103:481–490. doi: 10.1016/s0092-8674(00)00139-2. [DOI] [PMC free article] [PubMed] [Google Scholar] source
- Partly supportedcites [26] Bergers G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2000;2:737–744. doi: 10.1038/35036374. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) identifies mast cells and neutrophils as suppliers of MMP-9 in a model of squamous carcinogenesis, and reports that MMP-9 can mobilize VEGF during angiogenesis. Our copy does not establish the claimed roles for eosinophils or activated T lymphocytes, or say that these cells contribute by releasing chemokines. (LLM, conf=0.87)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
In the paper
“Indeed, macrophage infiltration is closely associated with the depth of invasion of primary melanoma due, in part, to macrophage-regulated tumour-associated angiogenesis19.”
What the sources say
- Not checked yetcites [19] Ono M, Torisu H, Fukushi J, Nishie A, Kuwano M. Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother Pharmacol. 1999;43:S69–S71. doi: 10.1007/s002800051101. [DOI] [PubMed] [Google Scholar] source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
76 more claims
Create a free account to see all 107 claims and to verify the 86 references still open.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 22
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chronic inflammation is also important for carcinogenesis, as pro-inflammatory cytokines, including IL-1β, can be tumour promoting6,111.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“many of these processes also occur in cancer as most of them are inflammation-related, including hypoxia-induced neovascularization, endothelial dysfunction, permeability of the microvasculature and the upregulation of adhesion molecules to facilitate the recruitment of cells30,31.”
From Perspectives and opportunities for nanomedicine in the management of atherosclerosis (2011) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inflammatory cells such as macrophages and neutrophils can cause immunosuppression in the TME.”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [94]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides promoting cell proliferation, the action of cytokines in promoting cancer development includes antagonizing anti-tumor immune response, recruiting tumor-supportive stromal cells and immune-suppressive cells, inducing angiogenesis and metastasis, and altering the responses to therapeutic agents (10, 15)”
From Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis (2021) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, rather than the dogma that oncogenesis is intrinsically triggered in pre-neoplastic cells, environmental factors, such as infection, stress, obesity, aging and smoking, each of which can induce chronic inflammation, could be a major cause of oncogenesis (4, 6, 9, 233).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [4]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Self-citationInvolvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
A DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Self-citationMatrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
Self-citationThe Biology of Chemokines and their Receptors
Rossi, D., & Zlotnik, A. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.217 · Cited by 2,410 · cited 1×
“A family of chemotactic cytokines, named chemokines, which possess a relatively high degree of specificity for chemoattraction of specific leukocyte population”
Cited by
Items 901–1,000 of 1,179
Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation
Pedroza-Gonzalez, A., Xu, K., Wu, T.-C., Aspord, C., Tindle, S., Marches, F., Gallegos, M., Burton, E. C., Savino, D., Hori, T., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20102131 · Cited by 237
Raiten, D. J., Ashour, F. A. S., Ross, A. C., Meydani, S. N., Dawson, H. D., Stephensen, C. B., Brabin, B. J., Suchdev, P. S., & van Ommen, B. (2015) · The Journal of Nutrition · doi:10.3945/jn.114.194571 · Cited by 234
Deryugina, E. I., & Quigley, J. P. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2009.09.017 · Cited by 238
Belletti, B., Vaidya, J. S., D'Andrea, S., Entschladen, F., Roncadin, M., Lovat, F., Berton, S., Perin, T., Candiani, E., Reccanello, S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4453 · Cited by 234
Matrix Metalloproteinases: A challenging paradigm of cancer management
Alaseem, A., Alhazzani, K., Dondapati, P., Alobid, S., Bishayee, A., & Rathinavelu, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.008 · Cited by 232
Zhang, Y., Daquinag, A. C., Amaya-Manzanares, F., Sirin, O., Tseng, C., & Kolonin, M. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0294 · Cited by 233
Neilson, H. K., Friedenreich, C. M., Brockton, N. T., & Millikan, R. C. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0756 · Cited by 232
Inflammation and cancer: Role of nuclear factor‐kappaB activation
Maeda, S., & Omata, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00763.x · Cited by 231
Remodeling of the Mammary Microenvironment after Lactation Promotes Breast Tumor Cell Metastasis
McDaniel, S. M., Rumer, K. K., Biroc, S. L., Metz, R. P., Singh, M., Porter, W., & Schedin, P. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050677 · Cited by 234
Zhang, L., Zhang, L., Deng, H., Li, H., Tang, W., Guan, L., Qiu, Y., Donovan, M. J., Chen, Z., & Tan, W. (2021) · Nature Communications · doi:10.1038/s41467-021-22286-x · Cited by 231
Obesity and cancer pathogenesis
Berger, N. A. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12416 · Cited by 231
The tumor microenvironment: a critical determinant of neoplastic evolution
van Kempen, L. C. L. T., Ruiter, D. J., van Muijen, G. N. P., & Coussens, L. M. (2003) · European Journal of Cell Biology · doi:10.1078/0171-9335-00346 · Cited by 231
Self-citationYe, X., Li, Y., Stawicki, S., Couto, S., Eastham-Anderson, J., Kallop, D., Weimer, R., Wu, Y., & Pei, L. (2010) · Oncogene · doi:10.1038/onc.2010.268 · Cited by 232
Insulin resistance and hyperinsulinaemia in the development and progression of cancer
Godsland, I. F. (2010) · Clinical Science · doi:10.1042/cs20090399 · Cited by 231
Thyroid cancer and inflammation
Guarino, V., Castellone, M. D., Avilla, E., & Melillo, R. M. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.10.003 · Cited by 227
Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis
Xiao, W.-K., Chen, D., Li, S.-Q., Fu, S.-J., Peng, B.-G., & Liang, L.-J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-117 · Cited by 231
Khosravi, N., Stoner, L., Farajivafa, V., & Hanson, E. D. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.08.187 · Cited by 230
The Role of Mitochondria in Inflammation: From Cancer to Neurodegenerative Disorders
Missiroli, S., Genovese, I., Perrone, M., Vezzani, B., Vitto, V. A. M., & Giorgi, C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030740 · Cited by 234
Tumor Hypoxia: Impact on Radiation Therapy and Molecular Pathways
Sørensen, B. S., & Horsman, M. R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00562 · Cited by 229
EMT and Oxidative Stress: A Bidirectional Interplay Affecting Tumor Malignancy
Giannoni, E., Parri, M., & Chiarugi, P. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4280 · Cited by 231
Tumors and inflammatory infiltrates: Friends or foes?
Brigati, C., Noonan, D. M., Albini, A., & Benelli, R. (2002) · Clinical & Experimental Metastasis · doi:10.1023/a:1015587423262 · Cited by 230
Role of Innate Immunity in Helicobacter pylori-Induced Gastric Malignancy
Peek, R. M., Fiske, C., & Wilson, K. T. (2010) · Physiological Reviews · doi:10.1152/physrev.00039.2009 · Cited by 230
Targeting Inflammatory Pathways by Flavonoids for Prevention and Treatment of Cancer
Prasad, S., Phromnoi, K., Yadav, V., Chaturvedi, M., & Aggarwal, B. (2010) · Planta Medica · doi:10.1055/s-0030-1250111 · Cited by 229
The Warburg effect: Evolving interpretations of an established concept
Chen, X., Qian, Y., & Wu, S. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.08.027 · Cited by 229
Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment
Kopfstein, L., & Christofori, G. (2006) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s00018-005-5296-8 · Cited by 229
Podoplanin in Inflammation and Cancer
Quintanilla, M., Montero-Montero, L., Renart, J., & Martín-Villar, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030707 · Cited by 234
Luppi, F., Longo, A. M., de Boer, W. I., Rabe, K. F., & Hiemstra, P. S. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2006.11.014 · Cited by 228
Serum amyloid A: An acute-phase protein involved in tumour pathogenesis
Malle, E., Sodin-Semrl, S., & Kovacevic, A. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8321-x · Cited by 234
Expression of CCL5 (RANTES) and CCR5 in prostate cancer
Vaday, G. G., Peehl, D. M., Kadam, P. A., & Lawrence, D. M. (2006) · The Prostate · doi:10.1002/pros.20306 · Cited by 230
Targeting immune cells for cancer therapy
Gun, S. Y., Lee, S. W. L., Sieow, J. L., & Wong, S. C. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101174 · Cited by 229
Bayala, B., Bassole, I. H. N., Gnoula, C., Nebie, R., Yonli, A., Morel, L., Figueredo, G., Nikiema, J.-B., Lobaccaro, J.-M. A., & Simpore, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092122 · Cited by 223
Platelet Granule Secretion Continuously Prevents Intratumor Hemorrhage
Ho-Tin-Noé, B., Goerge, T., Cifuni, S. M., Duerschmied, D., & Wagner, D. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0718 · Cited by 229
Powell, A. E., Anderson, E. C., Davies, P. S., Silk, A. D., Pelz, C., Impey, S., & Wong, M. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3223 · Cited by 227
De Francesco, E. M., Lappano, R., Santolla, M. F., Marsico, S., Caruso, A., & Maggiolini, M. (2013) · Breast Cancer Research · doi:10.1186/bcr3458 · Cited by 227
Chen, P., Huang, Y., Bong, R., Ding, Y., Song, N., Wang, X., Song, X., & Luo, Y. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1354 · Cited by 227
Caetano, M. S., Zhang, H., Cumpian, A. M., Gong, L., Unver, N., Ostrin, E. J., Daliri, S., Chang, S. H., Ochoa, C. E., Hanash, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2840 · Cited by 225
NLRP3 Inflammasome Activation in Cancer: A Double-Edged Sword
Hamarsheh, S., & Zeiser, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01444 · Cited by 230
Changes in Circulating MicroRNAs Are Associated With Childhood Obesity
Prats-Puig, A., Ortega, F. J., Mercader, J. M., Moreno-Navarrete, J. M., Moreno, M., Bonet, N., Ricart, W., López-Bermejo, A., & Fernández-Real, J. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1496 · Cited by 226
Deng, L., Zhou, J.-F., Sellers, R. S., Li, J.-F., Nguyen, A. V., Wang, Y., Orlofsky, A., Liu, Q., Hume, D. A., Pollard, J. W., et al. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090622 · Cited by 228
Non-genetic engineering of cells for drug delivery and cell-based therapy
Wang, Q., Cheng, H., Peng, H., Zhou, H., Li, P. Y., & Langer, R. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.12.003 · Cited by 225
Physiological and pathophysiological functions of intestinal mast cells
Bischoff, S. C. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0165-4 · Cited by 226
Wang, D.-S., Luo, H.-Y., Qiu, M.-Z., Wang, Z.-Q., Zhang, D.-S., Wang, F.-H., Li, Y.-H., & Xu, R.-H. (2012) · Medical Oncology · doi:10.1007/s12032-012-0226-8 · Cited by 224
Potential anti-inflammatory natural products from marine algae
Fernando, I. P. S., Nah, J.-W., & Jeon, Y.-J. (2016) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2016.09.023 · Cited by 225
Regulation of Tumor Progression by Programmed Necrosis
Lee, S. Y., Ju, M. K., Jeon, H. M., Jeong, E. K., Lee, Y. J., Kim, C. H., Park, H. G., Han, S. I., & Kang, H. S. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/3537471 · Cited by 215
Li, Z.-H., Chen, Y., Sun, Y., & Zhang, X.-Z. (2021) · ACS Nano · doi:10.1021/acsnano.0c10388 · Cited by 225
Kobayashi, S., Werneburg, N. W., Bronk, S. F., Kaufmann, S. H., & Gores, G. J. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.010 · Cited by 226
Bian, X., Tu, P., Chi, L., Gao, B., Ru, H., & Lu, K. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.04.045 · Cited by 216
Recruitment of monocytes/macrophages in different tumor microenvironments
Lee, H.-W., Choi, H.-J., Ha, S.-J., Lee, K.-T., & Kwon, Y.-G. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.12.007 · Cited by 222
Does measurement of oxidative damage to DNA have clinical significance?
Cooke, M. S., Olinski, R., & Evans, M. D. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.09.009 · Cited by 225
Role of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Cancer Prevention and Cancer Promotion
Wong, R. S. Y. (2019) · Advances in Pharmacological Sciences · doi:10.1155/2019/3418975 · Cited by 211
Surgical stress and cancer progression: the twisted tango
Chen, Z., Zhang, P., Xu, Y., Yan, J., Liu, Z., Lau, W. B., Lau, B., Li, Y., Zhao, X., Wei, Y., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1058-3 · Cited by 223
Gu, X.-B., Tian, T., Tian, X.-J., & Zhang, X.-J. (2015) · Scientific Reports · doi:10.1038/srep12493 · Cited by 178
Inflammation in the context of oral cancer
Feller, L., Altini, M., & Lemmer, J. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.07.003 · Cited by 221
Merrell, M. A., Ilvesaro, J. M., Lehtonen, N., Sorsa, T., Gehrs, B., Rosenthal, E., Chen, D., Shackley, B., Harris, K. W., & Selander, K. S. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0007 · Cited by 223
Cancer stem cells: In the line of fire
Alison, M. R., Lin, W.-R., Lim, S. M. L., & Nicholson, L. J. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.03.003 · Cited by 225
Coulouarn, C., Corlu, A., Glaise, D., Guénon, I., Thorgeirsson, S. S., & Clément, B. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3317 · Cited by 224
Oxidative Stress and Carbonyl Lesions in Ulcerative Colitis and Associated Colorectal Cancer
Wang, Z., Li, S., Cao, Y., Tian, X., Zeng, R., Liao, D.-F., & Cao, D. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/9875298 · Cited by 219
Computational and Experimental Models of Cancer Cell Response to Fluid Shear Stress
Mitchell, M. J., & King, M. R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00044 · Cited by 221
Cancers make their own luck: theories of cancer origins
Jassim, A., Rahrmann, E. P., Simons, B. D., & Gilbertson, R. J. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00602-5 · Cited by 221
Küchler, A. M., Pollheimer, J., Balogh, J., Sponheim, J., Manley, L., Sorensen, D. R., De Angelis, P. M., Scott, H., & Haraldsen, G. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.080014 · Cited by 220
Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/– mast cells
Feng-Chun, Y., Ingram, D. A., Chen, S., Hingtgen, C. M., Ratner, N., Monk, K. R., Clegg, T., White, H., Mead, L., Wenning, M. J., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci19195 · Cited by 221
Inflammation, Microenvironment, and the Immune System in Cancer Progression
Keibel, A., Singh, V., & Sharma, M. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788453167 · Cited by 220
Dong, Q., Wang, X., Hu, X., Xiao, L., Zhang, L., Song, L., Xu, M., Zou, Y., Chen, L., Chen, Z., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201709648 · Cited by 221
Tumor microenvironment responsive drug delivery systems
He, Q., Chen, J., Yan, J., Cai, S., Xiong, H., Liu, Y., Peng, D., Mo, M., & Liu, Z. (2020) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2019.08.003 · Cited by 219
Mustafa, S., Koran, S., & AlOmair, L. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.896099 · Cited by 211
Neutrophils: important contributors to tumor progression and metastasis
Swierczak, A., Mouchemore, K. A., Hamilton, J. A., & Anderson, R. L. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9594-9 · Cited by 220
McDonald, B., Spicer, J., Giannais, B., Fallavollita, L., Brodt, P., & Ferri, L. E. (2009) · International Journal of Cancer · doi:10.1002/ijc.24409 · Cited by 222
Mast cells have a protumorigenic role in human thyroid cancer
Melillo, R. M., Guarino, V, Avilla, E., Galdiero, M. R., Liotti, F., Prevete, N., Rossi, F. W., Basolo, F., Ugolini, C., de Paulis, A., et al. (2010) · Oncogene · doi:10.1038/onc.2010.348 · Cited by 219
Fritsch, A., Loeckermann, S., Kern, J. S., Braun, A., Bösl, M. R., Bley, T. A., Schumann, H., von Elverfeldt, D., Paul, D., Erlacher, M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34292 · Cited by 221
Multiple changes in sialic acid biology during human evolution
Varki, A. (2009) · Glycoconjugate Journal · doi:10.1007/s10719-008-9183-z · Cited by 219
Ridnour, L. A., Windhausen, A. N., Isenberg, J. S., Yeung, N., Thomas, D. D., Vitek, M. P., Roberts, D. D., & Wink, D. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702761104 · Cited by 219
Mizutani, K., Sud, S., McGregor, N. A., Martinovski, G., Rice, B. T., Craig, M. J., Varsos, Z. S., Roca, H., & Pienta, K. J. (2009) · Neoplasia · doi:10.1593/neo.09988 · Cited by 220
Sustained IL-6/STAT-3 Signaling in Cholangiocarcinoma Cells Due to SOCS-3 Epigenetic Silencing
Isomoto, H., Mott, J. L., Kobayashi, S., Werneburg, N. W., Bronk, S. F., Haan, S., & Gores, G. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.10.037 · Cited by 219
Mignogna, M. D., Fedele, S., Lo Russo, L., Lo Muzio, L., & Bucci, E. (2004) · Oral Oncology · doi:10.1016/j.oraloncology.2003.08.001 · Cited by 221
Cancer Cachexia: Beyond Weight Loss
Bruggeman, A. R., Kamal, A. H., LeBlanc, T. W., Ma, J. D., Baracos, V. E., & Roeland, E. J. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.016832 · Cited by 221
Constructing Redox-Responsive Metal–Organic Framework Nanocarriers for Anticancer Drug Delivery
Lei, B., Wang, M., Jiang, Z., Qi, W., Su, R., & He, Z. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b19693 · Cited by 218
The evolving relationship of wound healing and tumor stroma
Foster, D. S., Jones, R. E., Ransom, R. C., Longaker, M. T., & Norton, J. A. (2018) · JCI Insight · doi:10.1172/jci.insight.99911 · Cited by 223
Wu, L., Chen, X., Zhao, J., Martin, B., Zepp, J. A., Ko, J. S., Gu, C., Cai, G., Ouyang, W., Sen, G., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150204 · Cited by 221
Circulating Inflammation Markers and Prospective Risk for Lung Cancer
Shiels, M. S., Pfeiffer, R. M., Hildesheim, A., Engels, E. A., Kemp, T. J., Park, J.-H., Katki, H. A., Koshiol, J., Shelton, G., Caporaso, N. E., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt309 · Cited by 222
Nutrition and colonic health: the critical role of the microbiota
OʼKeefe, S. J. (2008) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3282f323f3 · Cited by 217
Sutcliffe, P., Connock, M., Shyangdan, D., Court, R., Kandala, N.-B., & Clarke, A. (2013) · Health Technol Assess · doi:10.3310/hta17420 · Cited by 217
Zheng, L., Yang, W., Wu, F., Wang, C., Yu, L., Tang, L., Qiu, B., Li, Y., Guo, L., Wu, M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0203 · Cited by 221
Sequence Variants ofToll-Like Receptor 4Are Associated with Prostate Cancer Risk
Zheng, S. L., Augustsson-Bälter, K., Chang, B., Hedelin, M., Li, L., Adami, H.-O., Bensen, J., Li, G., Johnasson, J.-E., Turner, A. R., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3280 · Cited by 219
MIF-Dependent Control of Tumor Immunity
Noe, J. T., & Mitchell, R. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.609948 · Cited by 198
“Conversely, antiinflammatory/immunosuppressive “M2” TAMs promote wound healing and resolution of chronic inflammatory responses that would otherwise drive tumor initiation (65), but in the context of established tumors, M2-TAMs promote evasion of anti-tumor immunity (66–72), de novo neoangiogenesis (73, 74), and extra…”
BackgroundContribution of MyD88 to the Tumor Exosome-Mediated Induction of Myeloid Derived Suppressor Cells
Liu, Y., Xiang, X., Zhuang, X., Zhang, S., Liu, C., Cheng, Z., Michalek, S., Grizzle, W., & Zhang, H.-G. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090777 · Cited by 218
Ribatti, D., & Crivellato, E. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00810.x · Cited by 214
Wang, Q., Ni, H., Lan, L., Wei, X., Xiang, R., & Wang, Y. (2010) · Cell Research · doi:10.1038/cr.2010.52 · Cited by 219
Gupta, B., Bray, F., Kumar, N., & Johnson, N. W. (2017) · Cancer Epidemiology · doi:10.1016/j.canep.2017.09.003 · Cited by 215
Bhuyan, R., Bhuyan, S. K., Mohanty, J. N., Das, S., Juliana, N., & Juliana, I. F. (2022) · Biomedicines · doi:10.3390/biomedicines10102659 · Cited by 200
Xu, H., Zheng, X., Ai, J., & Yang, L. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109496 · Cited by 205
The GAIT system: a gatekeeper of inflammatory gene expression
Mukhopadhyay, R., Jia, J., Arif, A., Ray, P. S., & Fox, P. L. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.03.004 · Cited by 216
Estrogen action and prostate cancer
Nelles, J. L., Hu, W.-Y., & Prins, G. S. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.20 · Cited by 214
C-Reactive Protein and Risk of Lung Cancer
Chaturvedi, A. K., Caporaso, N. E., Katki, H. A., Wong, H.-L., Chatterjee, N., Pine, S. R., Chanock, S. J., Goedert, J. J., & Engels, E. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0454 · Cited by 217
Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape
Salazar-Onfray, F., López, M. N., & Mendoza-Naranjo, A. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.01.015 · Cited by 194
Evaluation of the association of chronic inflammation and cancer: Insights and implications
Nigam, M., Mishra, A. P., Deb, V. K., Dimri, D. B., Tiwari, V., Bungau, S. G., Bungau, A. F., & Radu, A.-F. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115015 · Cited by 205
Depression, social support, and beta-adrenergic transcription control in human ovarian cancer
Lutgendorf, S. K., DeGeest, K., Sung, C. Y., Arevalo, J. M., Penedo, F., Lucci, J., Goodheart, M., Lubaroff, D., Farley, D. M., Sood, A. K., et al. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.04.155 · Cited by 215
Transcriptional network governing the angiogenic switch in human pancreatic cancer
Abdollahi, A., Schwager, C., Kleeff, J., Esposito, I., Domhan, S., Peschke, P., Hauser, K., Hahnfeldt, P., Hlatky, L., Debus, J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705505104 · Cited by 215
Brenner, D. R., Boffetta, P., Duell, E. J., Bickeboller, H., Rosenberger, A., McCormack, V., Muscat, J. E., Yang, P., Wichmann, H. E., Brueske-Hohlfeld, I., et al. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kws151 · Cited by 216
Mediterranean diet, dietary polyphenols and low grade inflammation: results from the MOLI‐SANI study
Bonaccio, M., Pounis, G., Cerletti, C., Donati, M. B., Iacoviello, L., de Gaetano, G., & on behalf of the MOLI‐SANI Study Investigators (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12924 · Cited by 215
High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas
Le Gouvello, S., Bastuji-Garin, S., Aloulou, N., Mansour, H., Chaumette, M.-T., Berrehar, F., Seikour, A., Charachon, A., Karoui, M., Leroy, K., et al. (2008) · Gut · doi:10.1136/gut.2007.123794 · Cited by 214
Metadata
- Authors
- Coussens, L. M., & Werb, Z.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Nature
- Published
- 2002-12
- Volume
- 420
- Issue
- 6917
- Pages
- 860-867
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2803035
- OpenAlex
- W1965037168
- Cited by
- 15,111
- References
- 88
- Citations by year
- 2026: 328 · 2025: 590 · 2024: 701 · 2023: 849 · 2022: 873 · 2021: 934 · 2020: 858 · 2019: 827 · 2018: 742 · 2017: 775 · 2016: 756 · 2015: 773 · 2014: 776 · 2013: 749 · 2012: 689
- FWCI
- 15.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- V Foundation for Cancer Research
- Edward Mallinckrodt, Jr. Foundation
- Fondation pour la Recherche Médicale
- National Institutes of Health
- National Cancer Institute (P01CA072006, R01CA057621)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Keywords
- inflammation, cancer, tumor microenvironment, tumor progression, chronic inflammation, infection-associated cancer, inflammatory cells, tumor cell proliferation, cell migration, metastasis, innate immune signaling, selectins, chemokines, chemokine receptors
- MeSH terms
- Animals, Chronic Disease, Humans, Inflammation, Leukocytes, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Disease Progression, Chemokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.